Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test.
Conclusions: Intra-gastric pH and acid reflux were strongly suppressed by 20-mg vonoprazan. When patients with gastroesophageal reflux disease present symptoms after administration of 20-mg vonoprazan, the possibility of pathophysiologies other than acid reflux should be considered.
PMID: 30347936 [PubMed]
Source: Journal of Neurogastroenterology and Motility - Category: Gastroenterology Tags: J Neurogastroenterol Motil Source Type: research
More News: Acid Reflux | Brain | Gastroenterology | Gastroesophageal Reflux Disease | GERD | Health Insurance | Insurance | Japan Health | Neurology | Potassium | Proton Pump Inhibitors PPIs | Study